Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0027 | 0.4263 | 0.5 | |
Onchocerca volvulus | 0.0027 | 0.4263 | 0.5 | |
Echinococcus granulosus | lamin dm0 | 0.0027 | 0.4263 | 0.4263 |
Echinococcus granulosus | lamin | 0.0027 | 0.4263 | 0.4263 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0047 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0047 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0047 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0027 | 0.4263 | 0.4263 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0047 | 1 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0015 | 0.0438 | 0.0438 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0047 | 1 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0027 | 0.4263 | 0.4263 |
Echinococcus multilocularis | lamin | 0.0027 | 0.4263 | 0.4263 |
Echinococcus multilocularis | musashi | 0.0027 | 0.4263 | 0.4263 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0047 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0047 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0047 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0027 | 0.4263 | 0.4001 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0027 | 0.4263 | 0.4263 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.4263 | 0.4263 |
Brugia malayi | intermediate filament protein | 0.0027 | 0.4263 | 0.4001 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.4113 | 0.4113 |
Echinococcus multilocularis | lamin dm0 | 0.0027 | 0.4263 | 0.4263 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (functional) | = 10.05 uM | Huh7 cytotoxicity for Pf inhibitors | Novartis-GNF Malaria Box. | No reference |
CC50 | = 10.05 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
EC50 (functional) | = 0.473 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 0.473 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | = 1.04 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 1.04 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
IC50 (functional) | = 0.01124 uM | NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration | ChEMBL. | 22096101 |
IFI promiscuity index | = 0.22727 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
Schizont size (functional) | = 18.06 um | NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration | ChEMBL. | 22096101 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium yoelii | ChEMBL23 | 22096101 | |
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.